These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3827260)

  • 41. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer.
    Bos AM; De Vos FY; de Vries EG; Beijnen JH; Rosing H; Mourits MJ; van der Zee AG; Gietema JA; Willemse PH
    Eur J Cancer; 2005 Mar; 41(4):539-48. PubMed ID: 15737558
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
    Liu J; Kraut EH; Balcerzak S; Grever M; D'Ambrosio S; Chan KK
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):445-53. PubMed ID: 12451470
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
    Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
    Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis.
    Molucon-Chabrot C; Isambert N; Benoit L; Zanetta S; Fraisse J; Guilland JC; Royer B; Monin-Baroille P; Flesch M; Fargeot P; Coudert B; Mayer F; Fumoleau P; Chauffert B
    Anticancer Drugs; 2006 Nov; 17(10):1211-7. PubMed ID: 17075321
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Pharmacokinetics of cis-dichlorodiammine platinum (II) in patients undergoing hemodialysis].
    Miyakawa M; Sugimoto K; Ohe Y; Masuoka H; Miyahara T
    Gan To Kagaku Ryoho; 1987 Aug; 14(8):2491-5. PubMed ID: 3619461
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Pharmacokinetics of CDDP by the route of administration in patients with ovarian cancer].
    Takada M; Usui N; Suzuki M; Furugen Y; Yamamoto T
    Nihon Sanka Fujinka Gakkai Zasshi; 1993 Feb; 45(2):99-105. PubMed ID: 8429253
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Intraperitoneal high-dose cisplatinum chemotherapy (CDDP-ip) in patients with carcinomatous peritonitis].
    Noda T; Oku M; Kiyozuka Y; Ninomiya Y; Hino K; Okamura Y; Maruyama M; Ichijo M
    Gan To Kagaku Ryoho; 1987 Apr; 14(4):1025-32. PubMed ID: 3566301
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications.
    Vermorken JB; van der Vijgh WJ; Klein I; Gall HE; Pinedo HM
    Eur J Cancer Clin Oncol; 1982 Nov; 18(11):1069-74. PubMed ID: 6891650
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Clinical pharmacokinetics of cis-diamminedichloroplatinum (DDP)].
    Zhang M
    Zhonghua Zhong Liu Za Zhi; 1992 Jan; 14(1):67-9. PubMed ID: 1396051
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma levels and urinary excretion of filterable platinum species following bolus injection and iv infusion of cis-dichlorodiammineplatinum(II) in man.
    Patton TF; Himmelstein KJ; Belt R; Bannister SJ; Sternson LA; Repta AJ
    Cancer Treat Rep; 1978 Sep; 62(9):1359-62. PubMed ID: 688279
    [No Abstract]   [Full Text] [Related]  

  • 52. Clinical pharmacology of intraperitoneal cisplatin.
    Lopez JA; Krikorian JG; Reich SD; Smyth RD; Lee FH; Issell BF
    Gynecol Oncol; 1985 Jan; 20(1):1-9. PubMed ID: 4038390
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Measuring cis-dichlorodiamino platinum(II) concentrations in human blood and mouth mucosa].
    Klima A; Haas G; Oremek G
    Laryngol Rhinol Otol (Stuttg); 1987 Nov; 66(11):598-600. PubMed ID: 3695774
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Regional pharmacokinetic selectivity of intraperitoneal cisplatin in ovarian cancer.
    Esposito M; Campora E; Repetto M; Fulco RA; Simoni GA; Falcone A; Collecchi P; Gogioso L; Nobile MT; Civalleri D
    Oncology; 1988; 45(2):69-73. PubMed ID: 3353075
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of the intraperitoneal and intravenous routes of cisplatin administration in an advanced ovarian cancer model of the rat.
    Sekiya S; Iwasawa H; Takamizawa H
    Am J Obstet Gynecol; 1985 Sep; 153(1):106-11. PubMed ID: 4041136
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics and tumor concentration of intraarterial and intravenous cisplatin in patients with head and neck squamous cancer.
    Sileni VC; Fosser V; Maggian P; Padula E; Beltrame M; Nicolini M; Arslan P
    Cancer Chemother Pharmacol; 1992; 30(3):221-5. PubMed ID: 1628371
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Platinum concentrations in bile and plasma following rapid and 6-hour infusions of cis-dichlorodiammineplatinum(II).
    Casper ES; Kelsen DP; Alcock NW; Young CW
    Cancer Treat Rep; 1979; 63(11-12):2023-5. PubMed ID: 575066
    [No Abstract]   [Full Text] [Related]  

  • 58. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin.
    Vermorken JB; van der Vijgh WJ; Klein I; Gall HE; van Groeningen CJ; Hart GA; Pinedo HM
    Clin Pharmacol Ther; 1986 Feb; 39(2):136-44. PubMed ID: 3943271
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Disposition of total and free cisplatin on two consecutive treatment cycles in patients with ovarian cancer.
    Erlichman C; Soldin SJ; Thiessen JJ; Sturgeon JF; Fine S
    Cancer Chemother Pharmacol; 1987; 19(1):75-9. PubMed ID: 3815729
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Correlation between free platinum AUC and total platinum measurement 24 h after i.v. bolus injection of cisplatin in humans.
    Fournier C; Vennin P; Hecquet B
    Cancer Chemother Pharmacol; 1988; 21(1):75-7. PubMed ID: 3342469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.